A novel 3-arylethynyl-substituted pyrido[2,3,-b]pyrazine derivatives and pharmacophore model as Wnt2/β-catenin pathway inhibitors in non-small-cell lung cancer cell lines

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 18, 2011, Pages 5639-5647

  Gong, Young Dae ^a   Dong, Mi Sook ^b   Lee, Sang Bum ^b   Kim, Nayeon ^a   Bae, Mi Seon ^a   Kang, Nam Sook ^c  

^a Dongguk University   (South Korea)

^b Korea University   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Catenin; Anti cancer; Inhibitors; Pharmacophore; Pyrido 2,3, b pyrazines; Wnt2

Indexed keywords

2 (1 METHYLPIPERIDIN 3 YLOXY) 3 (PHENYLETHYNYL)PYRIDO[3,2 B]PYRAZINE; 2 [3 [(3 FLUOROPHENYL)ETHYNYL]PYRIDO[3,2 B]PYRAZIN 2 YLOXY] N,N DIMETHYLETHAN AMINE; 2 [3 [(4 METHOXY 2 METHYLPHENYL)ETHYNYL]PYRIDO[3,2 B]PYRAZIN 2 YLOXY] N,N DIMETHYLETHAN AMINE; 2 CHLORO 3 (PHENYLETHYNYL)PYRIDO[3,2 B]PYRAZINE; 2 CHLORO 3 [(3 METHOXYPHENYL)ETHYNYL]PYRIDO[3,2 B]PYRAZINE; 2,3 DICHLOROPYRIDO[3,2 B]PYRAZINE; 3 (PHENYLETHYNYL) 2 [2 (PYRIDIN 2 YL)ETHOXY]PYRIDO[3,2 B]PYRAZINE; 3 (PHENYLETHYNYL) 2 [2 (PYRROLIDIN 1 YL)ETHOXY]PYRIDO[3,2 B]PYRAZINE; 3 [(3 FLUOROPHENYL)ETHYNYL] 2 [2 (PYRROLIDIN 1 YL)ETHOXY]PYRIDO[3,2 B]PYRAZINE; 3 [3 [(3 METHOXYPHENYL)ETHYNYL]PYRIDO[3,2 B]PYRAZIN 2 YLOXY] N,N DIMETHYLPROPAN 1 AMINE; 3 [3 [(3,5 DIMETHOXYPHENYL)ETHYNYL]PYRIDO[3,2 B]PYRAZIN 2 YLOXY] N,N DIMETHYLPROPAN 1 AMINE; 3 ARYLETHYNYL PYRIDO[2,3, B]PYRAZINE DERIVATIVE; BETA CATENIN INHIBITOR; N [2 [3 [(3 FLUOROPHENYL)ETHYNYL]PYRIDO[3,2 B]PYRAZIN 2 YLOXY]THYL] N ISOPROPYLPROPAN 2 AMINE; N,N DIETHYL 2 [3 [(4 METHOXYPHENYL)ETHYNYL]PYRIDO[3,2 B]PYRAZIN 2 YLOXY]ETHAN AMINE; N,N DIMETHYL 2 [3 (4 TOLYLETHYNYL)PYRIDO[3,2 B]PYRAZIN 2 YLOXY]PROPAN 1 AMINE; N,N DIMETHYL 3 [[3 (PHENYLETHYNYL)PYRIDO[3,2 B]PYRAZIN 2 YLOXY]METHYL]ANILINE; PROTEIN INHIBITOR; PYRIDO[3,2 B]PYRAZINE 2,3 DIOL; UNCLASSIFIED DRUG; WNT2 PROTEIN INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEN BOND; HYDROPHOBICITY; IC 50; LUNG NON SMALL CELL CANCER; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BETA CATENIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRAZINES; PYRIDINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; WNT PROTEINS;

EID: 80052592243     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.07.028     Document Type: Article

References (36)

1. R.T. Moon, J.D. Brown, and M. Torres Trends Genet. 13 1997 157
2. R. Nusse Trends Genet. 15 1999 1
3. D.R. Chesire, C.M. Ewing, J. Sauvageot, G.S. Bova, and W.B. Isaacs Prostate 45 2000 323
4. P.J. Morin, A.B. Sparks, V. Korinek, N. Barker, H. Clevers, B. Vogelstein, and K.W. Kinzler Science 275 1997 1787
5. M. Van Scoyk, J. Randall, A. Sergew, L.M. Williams, M. Tennis, and R.A. Winn Transl. Res. 151 2008 175
6. M. Katoh Int. J. Oncol. 19 2001 1003
7. J.K. Park, J.H. Song, T.C. He, S.W. Nam, J.Y. Lee, and W.S. Park Neoplasma 56 2009 119
8. X.X. Cheng, Z.C. Wang, X.Y. Chen, Y. Sun, Q.Y. Kong, J. Liu, and H. Li Cancer Lett. 223 2005 339
9. O. Watanabe, H. Imamura, T. Shimizu, J. Kinoshita, T. Okabe, A. Hirano, K. Yoshimatsu, S. Konno, M. Aiba, and K. Ogawa Anticancer Res. 24 2004 3851
10. L. You, B. He, Z. Xu, K. Uematsu, J. Mazieres, I. Mikami, N. Reguart, T.W. Moody, J. Kitajewski, F. McCormick, and D.M. Jablons Oncogene 23 2004 6170
11. N. Barker, and H. Clevers Nat. Rev. Drug Disc. 5 2006 997
12. M. McMillan, and M. Kahn Drug Discovery Today 10 2005 1467
13. S. Saraswati, M.P. Alfaro, C.A. Thorn, J. Atkinson, E. Lee, and P.P. Young PLoS One 5 2010 e15521
14. J. Lu, Z. Ma, J.-C. Hsieh, C.-W. Fan, B. Chen, J.C. Longgood, N.S. Williams, J.F. Amatruda, L. Lum, and C. Chen Bioorg. Med. Chem. Lett. 19 2009 3825
15. J.M. William, C.K. Jeffrey, B. Ramesh, V.N.B. Peter, S. Fukuyama, G. Krishnamurthy, L.M. Ronald, P. Keith, S. Barb, and J.T. Eugene Bioorg. Med. Chem. 18 2010 190
16. K. Kouken, A.A. Midori, X. Li, and I. Masami Bioorg. Med. Chem. Lett. 15 2007 4254
17. H. Wang, J. Hao, and C. Hong Chem. Biol. 6 2011 192
18. S.-B. Lee, Y.I. Park, M.S. Dong, and Y.-D. Gong Bioorg. Med. Chem. Lett. 20 2010 5900
19. 15 more than 20,000 small molecules by combinatorial synthetic technology. In the first stage, we selected 1434 representative compounds by virtual screening based on drug-like property considering with known Wnt pathway inhibiters.
20. Y.-D. Gong, and T. Lee J. Comb. Chem. 12 2010 393
21. J.Y. Hwang, H.-S. Choi, J.-S. Seo, H.-J. La, S.-E. Yoo, and Y.D. Gong J. Comb. Chem. 8 2006 897
22. J.Y. Hwang, and Y.D. Gong J. Comb. Chem. 8 2006 297
23. J.Y. Hwang, H.S. Choi, D.H. Lee, S.E. Yoo, and Y.D. Gong J. Comb. Chem. 7 2005 136
24. J.Y. Hwang, H.S. Choi, D.H. Lee, and Y.D. Gong J. Comb. Chem. 7 2005 816
25. I.Y. Lee, S.Y. Kim, J.Y. Lee, C.-M. Yu, D.H. Lee, and Y.D. Gong Tetrahedron Lett. 45 2004 9319
26. Gong, Y.-D.; Jeon, M. K.; Hwang, S. H.; Dong, M. S.; Lee, S. B.; Kang, K. H.; Oh, C. H. Novel 2-Sustituted Aminoalkylenyloxy-3-Substituted Phenyl Ethynyl Quinoxaline Derivatives, Korea Pat. No. 0889389.
27. Gong, Y.-D.; Dong, M. S.; Hwang, S. H.; Lee, T. I.; Lee, S. B. 2-Sustituted Aminoalkylenyloxy-3-Substituted Phenylethynyl-6-Amino Quinoxaline, Korea Pat. Appl. No. 2008-0076221.
28. Cell proliferation assay: Cell proliferation was determined by using a CellTiter 96 non-radioactive cell proliferation assay kit according to the manufacturer's protocol (Promega, USA). The detail procedure was mentioned in biological experimental part.
29. Lee, S. J.; Gong, Y.-D.; Jeon, M. K.; Moon, S. H.; Jun, K. H.; Kim, J. M.; Lee, S. H.; Lee, H. H.; Kang, M. J. 2-Arylalkylenyloxy-3-Ethynylpyrido[2,3- b] Pyrazine Derivatives, Korea Pat. App. No. 2006-0063214.
30. We checked cytotoxicity of the 13 compounds in human lung fibroblast cell line (LL47) and were over 0.5-1.0 μM higher than those in A549 cells.
31. In the early stage of our research, we used Calphostin C as positive control since we could not obtain other known comparison inhibitors from commercial market. And then we have synthesized and used the Pfizer lead compound (Data Monitor Research Store: preclinical stage, pyrinium pamoate) as positive control.
32. B.C.Y. Wong, X.H. Jiang, X.M. Fan, M.C.M. Lin, S.H. Jiang, S.K. Lam, and H.F. Kung Oncogene 22 2003 1189
33. T. Chalet, G.N. Rita, J.R. Anthony, P. Beata, K. Fatima, Z. Zhaobin, Z. Huanchun, T. Quincy, C.N. Ainsley, G. Paraskevi, Z. Wei, J.O. Jeffrey, M.P. Manuela, K.C. Nicolaou, and G.V.M. Erwin Cancer Res. 65 2005 605
34. Concord; Tripos Inc., 1699 South Hanley Road, St. Louis, MO 63144.
35. Catalyst User Guide, Accelrys Software Inc., San Diego, 2005.
36. Y.-D. Gong, and N.S. Kang Bull. Korean Chem. Soc. 31 2010 2039